Close

Clinical phase III studies of Lu AA21004 presented for the first time at the 2011 Annual Meeting

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Ensuring optimal product integrity with pharmaceutical preservation strategies

Preserving the potency of pharmaceutical products is paramount in...

How Stem Cell Therapy Works for the Individual

Stem cell therapy has emerged as one of the...

Tjoapack Expands Injectable Packaging Capabilities Globally

Increased Capabilities in the United States Tjoapack is finishing up...

H. Lundbeck A/S announced the presentation of new data from the clinical phase III program of Lu AA21004, an investigational compound for the treatment of adult patients with major depressive disorder (MDD), at the 2011 Annual Meeting of the American Psychiatric Association (APA) in Honolulu, Hawaii. The presentations included results from four placebo-controlled clinical phase III studies as well as pre-clinical data. “The data from the phase III studies continue to support Lu AA21004 as a multimodal anti-depressant based on its safety, efficacy as well as its relapse prevention profile”, says Executive Vice President Anders Gersel Pedersen, Head of Drug Development at Lundbeck, and continues: “With the ongoing development programme of Lu AA21004, we are building on Lundbeck’s market leadership position and our commitment to advancing medical treatment for one of the most prevalent and debilitating psychiatric disorders.”

The annual meeting of the APA is one of the largest scientific meetings for psychiatrists and other healthcare professionals involved in psychiatric research and psychiatric care.

In the U.S., Lundbeck is partnering with Takeda Global Research and Development Center Inc., U.S. on the co-development and co-commercialization of this compound. There are currently four ongoing short-term depression studies and two long-term safety studies. 

Latest stories

Related stories

Ensuring optimal product integrity with pharmaceutical preservation strategies

Preserving the potency of pharmaceutical products is paramount in...

How Stem Cell Therapy Works for the Individual

Stem cell therapy has emerged as one of the...

Tjoapack Expands Injectable Packaging Capabilities Globally

Increased Capabilities in the United States Tjoapack is finishing up...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back